Rivastigmine (Exelon) prior authorization and coverage criteria
Customize your policy alerts
Sign up for Delaware First Health Policy CP.PMN.101 alerts
Get alerted when Policy CP.PMN.101 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing limits, and prior authorization requirements for rivastigmine (Exelon) products for Delaware First Health Medicaid members, including Alzheimer’s disease and Parkinson's disease dementia.
No material clinical or coverage changes in this revision.
Coverage Criteria for Rivastigmine (Exelon)
Initial Therapy — Alzheimer's
Initial Approval Criteria — Alzheimer's Dementia (must meet all):
Approval duration: 12 months
Initial Therapy — PDD
Initial Approval Criteria — Parkinson's Disease Dementia (must meet all):
Approval duration: 12 months
Continued Therapy
Continued Therapy (All indications in Section I — must meet all):
Approval duration: 12 months
Other / Off-label
Other indications / Off-label use:
Approval duration: 12 months
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the request includes sufficient documentation of efficacy and safety in accordance with the Health Plan's off‑label use policy CP.PMN.53 or the member's evidence of coverage documents. Providers requesting coverage for such uses must supply clinical rationale and supporting records demonstrating that the proposed indication meets those off‑label evidentiary standards.
All coverage determinations described in this clinical policy are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance), applicable state and federal law, and Health Plan administrative policies and procedures. This policy is a guide to medical necessity and does not guarantee payment; providers must follow Health Plan procedures when requesting coverage.
Provider Actions, Prior Authorization, and Documentation Requirements
Prior authorization requires meeting diagnostic, age, trial, and dosing criteria
Prior authorization is required and will be approved only when the member meets the policy’s diagnostic, age, prior-trial, and dosing criteria. Approval duration for both initial and continued therapy is 12 months.
- Must meet all applicable criteria listed under Initial Approval or Continued Therapy (e.g., diagnosis, age ≥ 18, prior-trial requirements where applicable, and dose limits).
- Approval duration: 12 months.
PA governed by Health Plan coverage documents and administrative policies
Prior authorization requests for rivastigmine must be submitted according to the member’s Health Plan coverage documents and the Health Plan’s administrative policies and procedures.
- Follow the plan’s evidence of coverage, certificate, policy, contract, and Health Plan-level administrative procedures when seeking prior authorization.
Required prior trials for Alzheimer’s (step therapy/prior trial)
For Alzheimer’s dementia, prior trials are required unless contraindicated: failure of a ≥3 month trial of donepezil at ≥10 mg/day or galantamine 24 mg/day, or intolerance/contraindication to both plus failure of a ≥3 month trial of memantine at ≥20 mg/day (unless contraindicated).
- Alzheimer’s step requirement: failure of ≥3 months of donepezil ≥10 mg/day OR galantamine 24 mg/day.
- If intolerant/contraindicated to both donepezil and galantamine, require failure of ≥3 months of memantine ≥20 mg/day unless contraindicated.
No other explicit step therapy program specified in document chunks
The reviewed document chunks do not specify any additional or alternative step therapy requirements beyond those stated for Alzheimer’s and PDD; no separate explicit step therapy program is described in these sections.
- Use the specific prior-trial language in the Initial Approval sections; no other step therapy program is defined in the cited document sections.
Submit supporting clinical documentation with PA requests
Providers must submit supporting clinical documentation with PA requests, such as office chart notes, laboratory results, and other relevant clinical information demonstrating that the member meets all approval criteria.
- Include office chart notes, labs, and any other clinical information that documents diagnosis, prior trials, dosing, and intolerance/contraindication as applicable.
Follow Health Plan coverage documents and administrative procedures when requesting coverage
When requesting coverage, providers should follow the Health Plan’s coverage documents and administrative procedures; this clinical policy is a guide to medical necessity but does not guarantee payment.
- This policy guides medical necessity determinations but providers must adhere to plan-level rules and procedures for authorization and payment.
- Providers remain responsible for exercising professional judgment in treatment decisions.
Insufficient documentation or non‑FDA indications risk denial
Requests that lack documentation showing the member meets the approval criteria, or requests for non‑FDA indications without sufficient evidence per the off‑label use policy, may be denied.
- Insufficient documentation of required prior trials, diagnosis, age, dosing, or intolerance/contraindication puts the request at risk for denial.
- Non‑FDA (off‑label) indications require sufficient documentation of efficacy and safety per CP.PMN.53; absence of such documentation may result in denial.
Coverage subject to terms, conditions, exclusions, and limitations of coverage documents
Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the member’s coverage documents and applicable Health Plan administrative policies; these terms take precedence where applicable.
- Evidence of coverage, certificate of coverage, policy, contract of insurance, and state/federal requirements govern coverage specifics and limitations.
- The Health Plan may change, amend, or withdraw this clinical policy and other administrative policies may apply.
Definitions and Abbreviations
Background
Rivastigmine is an acetylcholinesterase inhibitor used in the management of dementia. It is available in oral capsule formulations and as a transdermal patch, with formulation‑specific dosing and titration schedules. The oral capsule and patch products are approved for Alzheimer's disease (mild to moderate), and rivastigmine is also FDA‑approved for Parkinson's disease dementia (PDD); the transdermal patch additionally has an indication that includes severe Alzheimer's disease. Typical product selection and dose limits differ by formulation, and the policy specifies maximum covered doses by route.
Policy Revision History
1Q 2025 annual review: revised policy/criteria section to also include brand Exelon; references reviewed and updated.
1Q 2026 annual review: no significant changes; references reviewed.
1Q 2024 annual review: no significant changes; references reviewed and updated.
1Q 2023 annual review: no significant changes; added requirement to use generic rivastigmine patches; references reviewed and updated.
1Q 2022 annual review: references reviewed and updated; template changes applied to other diagnoses/indications and continued therapy section.
References reviewed and updated (entry noted 09.16.21).
Policy effective date recorded as 2017-03-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.